Non-infectious uveitis: A review of clinical, diagnostic and therapeutic approach to the disease
DOI:
https://doi.org/10.33448/rsd-v13i7.44810Keywords:
Non-infectious uveitis; Diagnosis; Treatment.Abstract
The incidence of non-infectious uveitis (NIU) is influenced by genetic and environmental factors. This disease has a clinical picture similar to other eye pathologies, it becomes difficult to obtain accurate diagnosis. The research aims to review the clinical, diagnostic and therapeutic approach of NIU. To achieve this objective, there was a bibliographic review study based on therapeutic guidelines and scientific articles published in MedLINE from 2018 to 2023. The evidence presented based on the investigated literature gives us that before starting to the Therapy, it is necessary to perform the proper diagnosis and choose the best therapy that preserves anatomical structures and improves the patient's vision. In addition, it is worth mentioning that the base of NIU treatment remains immunosuppressants and corticosteroids, the latter known for having eye and systemic side effects. Currently to minimize these effects, therapy has been introduced with biological products, which provides better visual acuity, reduces intraocular inflammation, decreases the systemic dose of corticosteroids and minimizes adverse effects. However, its use requires caution as it has already been reported to occur demyelinating disorders in a small group of patients. NIU is always associated with a systemic or idiopathic autoimmune condition. Thus, for a good clinical, diagnostic and therapeutic approach, it is necessary that there is close collaboration between the ophthalmologist and doctors of other specialties (rheumatologist) to have an accurate diagnosis and discard other associated comorbidities, avoiding complications that cause blindness.
References
Abraham, A., Nicholson, L., Dick, A., Rice, C., & Atan, D. (2021). Intermediate uveitis associated with MS. Neurology - Neuroimmunology Neuroinflammation, 8(1), 1–11. https://doi.org/10.1212/NXI.0000000000000909
Balasubramaniam, B., Chong, Y. J., Azzopardi, M., Logeswaran, A., & Denniston, A. K. (2022). Topical Anti-Inflammatory Agents for Non-Infectious Uveitis: Current Treatment and Perspectives. Journal of Inflammation Research, Volume 15(November), 6439–6451. https://doi.org/10.2147/JIR.S288294
Bertrand, P., Jamilloux, Y., Ecochard, R., Richard-Colmant, G., Gerfaud-Valentin, M., Guillaud, M., Denis, P., Kodjikian, L., & Sève, P. (2019). Uveitis: Autoimmunity… and beyond. Autoimmunity Reviews, 18(9), 102351. https://doi.org/10.1016/j.autrev.2019.102351
Bonnet, C., & Brézin, A. (2020). Uvéites, éléments d’orientation diagnostique. Journal Français d’Ophtalmologie, 43(2), 145–151. https://doi.org/10.1016/j.jfo.2019.03.038
Burek-Michalska, A., & Turno-Kręcicka, A. (2020). Adalimumab in the treatment of non-infectious uveitis. Advances in Clinical and Experimental Medicine, 29(10), 1231–1236. https://doi.org/10.17219/acem/125431
Burkholder, B. M., & Jabs, D. A. (2021). Uveitis for the non-ophthalmologist. BMJ, 372, m4979. https://doi.org/10.1136/bmj.m4979
Chang, M. H., Shantha, J. G., Fondriest, J. J., Lo, M. S., & Angeles-Han, S. T. (2021). Uveitis in Children and Adolescents. Rheumatic Disease Clinics of North America, 47(4), 619–641. https://doi.org/10.1016/j.rdc.2021.07.005
Cordeiro, A. M., Oliveira, G. M. de, Rentería, J. M., & Guimarães, C. A. (2007). Revisão sistemática: uma revisão narrativa. Revista Do Colégio Brasileiro de Cirurgiões, 34(6), 428–431. https://doi.org/10.1590/S0100-69912007000600012
Couret, C., Ducloyer, J., Touhami, S., Rougier, M., Labalette, P., Titah, C., Cochereau, I., Kodjikian, L., Mura, F., Chiquet, C., Weber, M., & Bodaghi, B. (2019). Traitement des uvéites intermédiaires , postérieures et panuvéites non infectieuses. Journal de Gynecologie Obstetrique et Biologie de La Reproduction. https://doi.org/10.1016/j.jfo.2019.03.033
Egwuagu, C. E., Alhakeem, S. A., & Mbanefo, E. C. (2021). Uveitis: Molecular Pathogenesis and Emerging Therapies. Frontiers in Immunology, 12(April), 1–11. https://doi.org/10.3389/fimmu.2021.623725
Gamalero, L., Simonini, G., Ferrara, G., Polizzi, S., Giani, T., & Cimaz, R. (2019). Evidence-Based Treatment for Uveitis. IMAJ, 21, 475–479. https://pubmed.ncbi.nlm.nih.gov/31507124/
Garweg, J. G. (2019). Grundzüge der medikamentösen Therapie und chirurgische Optionen bei Uveitis. Der Ophthalmologe, 116(10), 942–950. https://doi.org/10.1007/s00347-019-0870-x
Gozzi, F., Gentile, P., Simone, L. De, Bolletta, E., Alessandrello, F., Belloni, L., Bonacini, M., Croci, S., Zerbini, A., & Cimino, L. (2022). Viral anterior uveitis. Saudi Journal of Ophthalmology -, 36(4), 356–364. https://doi.org/10.4103/SJOPT.SJOPT
Gueudry, J., & Muraine, M. (2018). Anterior uveitis. Journal Français d’Ophtalmologie, 41(1), e11–e21. https://doi.org/10.1016/j.jfo.2017.11.003
Gupta, S., Shyamsundar, K., Agrawal, M., Vichare, N., & Biswas, J. (2022). Current Knowledge of Biologics in Treatment of Noninfectious Uveitis. Journal of Ocular Pharmacology and Therapeutics, 38(3), 203–222. https://doi.org/10.1089/jop.2021.0098
Hasegawa, E., Takeda, A., Yawata, N., & Sonoda, K.-H. (2019). The effectiveness of adalimumab treatment for non-infectious uveitis. Immunological Medicine, 42(2), 79–83. https://doi.org/10.1080/25785826.2019.1642080
Heiligenhaus, A., Rothaus, K., & Pleyer, U. (2021). Entwicklung von Klassifikationskriterien für Uveitiden von der Standardization of Uveitis Nomenclature (SUN) Working Group. Der Ophthalmologe, 118(9), 913–918. https://doi.org/10.1007/s00347-021-01486-2
Hiyama, T., Harada, Y., & Kiuchi, Y. (2022). Efficacy and Safety of Adalimumab Therapy for the Treatment of Non-infectious Uveitis: Efficacy comparison among Uveitis Aetiologies. Ocular Immunology and Inflammation, 30(4), 951–958. https://doi.org/10.1080/09273948.2020.1857791
Hou, S., Li, N., Liao, X., Kijlstra, A., & Yang, P. (2020). Uveitis genetics. Experimental Eye Research, 190, 107853. https://doi.org/10.1016/j.exer.2019.107853
Hysa, E., Cutolo, C. A., Gotelli, E., Pacini, G., Schenone, C., Kreps, E. O., Smith, V., & Cutolo, M. (2021). Immunopathophysiology and clinical impact of uveitis in inflammatory rheumatic diseases: An update. European Journal of Clinical Investigation, 51(8), 1–13. https://doi.org/10.1111/eci.13572
Jin, Y., Lu, S., Lin, Y., & Mou, X. (2022). The efficacy and safety of TNF inhibitor (golimumab) as salvage treatment in patients with refractory noninfectious uveitis. Inflammopharmacology, 30(4), 1363–1368. https://doi.org/10.1007/s10787-022-01019-6
Kalogeropoulos, D., Asproudis, I., Stefaniotou, M., Moschos, M. M., Kozobolis, V. P., Voulgari, P. V., Katsanos, A., Gartzonika, C., & Kalogeropoulos, C. (2023). The large Hellenic Study of Uveitis: epidemiology, etiologic factors and classification. International Ophthalmology, 43(10), 3633–3650. https://doi.org/10.1007/s10792-023-02772-5
Mattos, P. C. (2015). Tipos de revisão de literatura. https://www.fca.unesp.br/#!/biblioteca/normas-tecnicas/tipos-de-revisao-de-literatura/
Ministério da Saúde. (2020). Protocolo clínico e diretrizes terapêuticas das uveítes não infecciosas (Editora MS (ed.); 1a edição). http://bvsms.saude.gov.br/bvs/publicacoes/protocolo_clinico_terapeuticas
Oh, L. J., Nguyen, C. L., Phan, K., Wong, E., Zagora, S., Singh‐Grewal, D., Chaitow, J., Grigg, J. R., & McCluskey, P. (2019). Changing biological disease modifying treatment for paediatric uveitis in the real world. Clinical & Experimental Ophthalmology, 47(6), 741–748. https://doi.org/10.1111/ceo.13494
Pichi, F., Curi, A. L. L., Vasconcelos-Santos, D. V., Marchese, A., Cicinelli, M. V., Miserocchi, E., & Schlaen, A. (2022). Optical Coherence Tomography Findings in Infectious Posterior Uveitis. Ocular Immunology and Inflammation, 30(3), 652–663. https://doi.org/10.1080/09273948.2022.2032197
Rathinam, S., Tugal-Tutkun, I., Agarwal, M., Rajesh, V., Egriparmak, M., & Patnaik, G. (2020). Immunological tests and their interpretation in uveitis. Indian Journal of Ophthalmology, 68(9), 1737. https://doi.org/10.4103/ijo.IJO_570_20
Rother, E. T. (2007). Revisão sistemática X revisão narrativa. Acta Paulista de Enfermagem, 20(2), v–vi. https://doi.org/10.1590/S0103-21002007000200001
Shahab, M. A., Mir, T. A., & Zafar, S. (2019). Optimising drug therapy for non-infectious uveitis. International Ophthalmology, 39(7), 1633–1650. https://doi.org/10.1007/s10792-018-0984-1
Siddaway, A. P., Wood, A. M., & Hedges, L. V. (2019). How to Do a Systematic Review: A Best Practice Guide for Conducting and Reporting Narrative Reviews, Meta-Analyses, and Meta-Syntheses. Annual Review of Psychology, 70(1), 747–770. https://doi.org/10.1146/annurev-psych-010418-102803
Smeller, L., Sümegi, V., Tóth-Molnár, E., & Sohár, N. (2022). A biológiai terápia helye a gyermekkori uveitis ellátásában. Orvosi Hetilap, 163(35), 1402–1408. https://doi.org/10.1556/650.2022.32578
Sukhera, J. (2022). Narrative Reviews in Medical Education: Key Steps for Researchers. Journal of Graduate Medical Education, 14(4), 418–419. https://doi.org/10.4300/JGME-D-22-00481.1
Takeuchi, M., Mizuki, N., & Ohno, S. (2021). Pathogenesis of Non-Infectious Uveitis Elucidated by Recent Genetic Findings. Frontiers in Immunology, 12(April), 1–13. https://doi.org/10.3389/fimmu.2021.640473
The Standardization of Uveitis Nomenclature (SUN) Working Group. (2021a). Classification Criteria for Multiple Sclerosis-Associated Intermediate Uveitis. American Journal of Ophthalmology, 228, 72–79. https://doi.org/10.1016/j.ajo.2021.03.044
The Standardization of Uveitis Nomenclature (SUN) Working Group. (2021b). Development of Classification Criteria for the Uveitides. American Journal of Ophthalmology, 228, 96–105. https://doi.org/10.1016/j.ajo.2021.03.061
Therssen, S., Meers, S., Jacob, J., & Schauwvlieghe, P.-P. (2022). Brentuximab vedotin induced uveitis. American Journal of Ophthalmology Case Reports, 26, 101440. https://doi.org/10.1016/j.ajoc.2022.101440
Thomas, A. S. (2019). Biologics for the treatment of noninfectious uveitis. Current Opinion in Ophthalmology, 30(3), 138–150. https://doi.org/10.1097/ICU.0000000000000562
Tosi, G. M., Sota, J., Vitale, A., Rigante, D., Emmi, G., Lopalco, G., Guerriero, S., Orlando, I., Iannone, F., Frediani, B., Angotti, R., Messina, M., Galeazzi, M., Vannozzi, L., Cantarini, L., & Fabiani, C. (2019). Efficacy and safety of certolizumab pegol and golimumab in the treatment of non-infectious uveitis. Clinical and Experimental Rheumatology, 37(4), 680–683. https://pubmed.ncbi.nlm.nih.gov/30943133/
Wang, L., Guo, Z., Zheng, Y., Li, Q., Yuan, X., & Hua, X. (2021). Analysis of the clinical diagnosis and treatment of uveitis. Annals of Palliative Medicine, 10(12), 12782–12788. https://doi.org/10.21037/apm-21-3549
Watson, M. (2020). How to undertake a literature search: a step-by-step guide. British Journal of Nursing, 29(7), 431–435. https://doi.org/10.12968/bjon.2020.29.7.431
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 João Viriato Mazalo; Joel Bambamba; Ângela Bambamba; Yúria Moisés Gueve; Sílvia Rocha Afonso
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
